-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It is important to understand the patient's cancer treatment experience.
This study aims to evaluate the prognosis (PRO) reported by patients in the IMbrave150 trial.
The IMbrave150 trial is an open-label, randomized phase 3 trial conducted in 111 hospitals/cancer centers in 17 countries/regions.
From March 15, 2018 to January 30, 2019, a total of 725 patients were screened , of which 501 were recruited into the group and randomly assigned to the combination group (n=336) or sorafenib group (n= 165).
Screening
Changes in EORTC QLQ-C30 quality of life and functional scale assessment results during the first 5 courses of treatment in each treatment group
Changes in EORTC QLQ-C30 quality of life and functional scale assessment results during the first 5 courses of treatment in each treatment groupAs of August 29, 2019, the median follow-up was 8.
The median follow-up was 8.
Compared with sorafenib, atuzumab combined with bevacizumab treatment can reduce the risk of deterioration of the predetermined EORTC QLQ-C30 general cancer symptom scale and also reduce three EORTC QLQ-HCC18 disease-specific symptom scales Risk of deterioration of two of them
In summary, a scheduled analysis of PRO data shows that compared with sorafenib, patients treated with atolizumab combined with bevacizumab have reported clinically significant benefits in terms of quality of life, function, and disease symptoms.
Compared with sorafenib, patients treated with atolizumab combined with bevacizumab have reported clinically significant benefits in terms of quality of life, function, and disease symptoms
Original source:
Original source:Peter R Galle, et al.
org/10.
1016/S1470-2045(21)00151-0" target="_blank" rel="noopener">Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
in this message
